Recombinant DNA Technology in the Synthesis of Human Insulin

Pharmaceutical Products of Recombinant DNA Technology

Steps in recombinant DNA technology - Biology 4 U

The early success of recombinant DNA technology relies heavily on the elucidation of the biological possesses at the molecular level in microbial systems. The first commercial application is realized in the microbial production of human insulin.

Humulin is synthetic human insulin prepared by using genetic engineering. It is manufactured from DNA sources in laboratory, using recombinant DNA technology.

Glossary | Linus Pauling Institute | Oregon State University

This vial contains Novolin R, commonly known as Regular, Human Insulin Injection (recombinant DNA origin). The concentration of this product is 100 units of insulin per milliliter. It is a clear, colorless solution which has a short duration of action. The effect of Novolin R begins approximately ½ hour after injection. The effect is maximal between 2½ and 5 hours and ends approximately 8 hours after injection.

And in fact, insulin was the first ever pharmaceutical product of recombinant DNA technology administered to humans

This package contains five (5) Novolin R PenFill 3 mL cartridges. Novolin R is commonly known as Regular, Human Insulin Injection (recombinant DNA origin). The concentration of this product is 100 units of insulin per milliliter. It is a clear, colorless solution which has a short duration of action. The effect of Novolin R begins approximately ½ hour after injection. The effect is maximal between 2½ and 5 hours and ends approximately 8 hours after injection. The time course of action of any insulin may vary considerably in different individuals, or at different times in the same individual. Because of this variation, the time periods listed here should be considered as general guidance only. This human insulin (recombinant DNA origin) is structurally identical to the insulin produced by the human pancreas. This human insulin is produced by recombinant DNA technology utilizing (bakers' yeast) as the production organism.

Recombinant DNA comprising a plant chromosome and the human insulin gene provides plant cells and transgenic plants that can produce human insulin.


Humulin and its Advantages | Chemistry Learning

Regular, Human Insulin Injection (rDNA origin) USP is a polypeptide hormone structurally identical to natural human insulin and is produced by rDNA technology, utilizing (bakers' yeast) as the production organism. Human insulin has the empirical formula CHNOS and a molecular weight of 5808 Da.

Efficacy and Safety of Recombinant Human Activated …

In chemical and pharmacological studies, commercially available Recombinant DNA human insulin has proven indistinguishable from pancreatic human insulin. Initially the major difficulty encountered was the contamination of the final product by the host cells, increasing the risk of contamination in the fermentation broth.

Patent US6331415 - Methods of producing …

Genetic engineering is used for many different purposes in research, medicine, agriculture and industry. The technology is important because it enables the creation of multiple copies of genes and the insertion of foreign genes into other organisms to give them new traits, such as antibiotic resistance or a new colour. One of the first ways in which the technology was deployed was to re-engineer microbial cells to produce foreign proteins. This facilitated the manufacture of human proteins on an unprecedented scale at minimum cost, thereby opening the way to study the function of proteins in greater detail and to their therapeutic use. By 2001 over 80 recombinant DNA based products had been approved for treating disease and for vaccination and a further 350 recombinant DNA-based drugs were being tested for safety and efficacy. The technology is also an important tool in agriculture, being used to improve plants' resistance to pests and increase crop yields.